title: Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes.
abstract: To evaluate the capability of NK cells and cytotoxic T lymphocytes to interact with normal hematopoietic progenitor cells (HPC), as compared to neoplastic lymphohematopoietic cells, we investigated inhibition of colony growth of these cell populations in semi-solid culture systems, after incubation with cloned cytotoxic effector cells. Three different types of cloned effector cells were investigated: TCR-/CD3- NK cells, TCR-gamma delta+/CD3+ cells, and TCR-alpha beta+/CD3+ cytotoxic T lymphocytes. Effector cells showed differential levels of tumor cell colony inhibition, but no MHC-non-restricted lysis of normal HPC was observed. Pre-stimulation of normal HPC by culturing on established stromal layers had no effect. Cell-mediated lysis of HPC only occurred by Ag-specific MHC-restricted lysis by CTL, or by antibody-dependent cellular cytotoxicity. In cell mixing experiments, irradiated tumor cells, but not normal bone marrow cells inhibited tumor cell lysis. Furthermore, cloned effector lymphocytes were able to specifically eliminate malignant cells from tumor contaminated bone marrow without damaging normal HPC. When fresh leukemic cells were used as targets, growth of acute myeloblastic leukemia colonies was inhibited after incubation with several cytotoxic effector clones, whereas chronic myeloid leukemia precursor cells showed limited sensitivity to MHC-non-restricted cytolysis. These results indicate that MHC-non-restricted cytolysis by NK cells is selectively directed against neoplastic cells and not against normal HPC.
authors.affiliation: Department of Hematology, University Medical Center, Leiden, The Netherlands.
authors.forename: P J
authors.initials: PJ
authors.lastname: Voogt
authors.forename: J H
authors.initials: JH
authors.lastname: Falkenburg
authors.forename: W E
authors.initials: WE
authors.lastname: Fibbe
authors.forename: W F
authors.initials: WF
authors.lastname: Veenhof
authors.forename: M
authors.initials: M
authors.lastname: Hamilton
authors.forename: B A
authors.initials: BA
authors.lastname: Van Krimpen
authors.forename: R L
authors.initials: RL
authors.lastname: Bolhuis
mesh_terms: D000920:Antibody-Dependent Cell Cytotoxicity; D000943:Antigens, Differentiation / Q000502:physiology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D001853:Bone Marrow; D017252:CD3 Complex; D002478:Cells, Cultured; D002999:Clone Cells / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D005109:Extracellular Matrix / Q000276:immunology; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology*; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology; D008213:Lymphocyte Activation; D008212:Lymphocyte Depletion; D014411:Neoplastic Stem Cells / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D011961:Receptors, Fc / Q000502:physiology; D017452:Receptors, IgG; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism
chemical_list: D000943:Antigens, Differentiation; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D006680:HLA Antigens; D011948:Receptors, Antigen, T-Cell; D011961:Receptors, Fc; D017452:Receptors, IgG